Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge

Vaccine

Volumn 28, Issue 33, 2010, Pages 5451-5457

  Okwor, Ifeoma ^a   Kuriakose, Shiby ^a   Uzonna, Jude ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anti Leishmania immunity; Killed parasites; Protection; Vaccination

Indexed keywords

GAMMA INTERFERON; HERMES ANTIGEN; INACTIVATED VACCINE; L SELECTIN; LEISHMANIA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; INOCULATION; INTERFERON PRODUCTION; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; PROTECTION; VACCINATION;

ANIMALS; INTERFERON-GAMMA; INTERLEUKIN-12; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, INACTIVATED;

EID: 77955052282     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.077     Document Type: Article

References (33)

1. Ashford R.W., Kohestany K.A., Karimzad M.A. Cutaneous leishmaniasis in Kabul: observations on a 'prolonged epidemic'. Ann Trop Med Parasitol 1992, 86(4):361-371.
2. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996, 14(5):417-423.
3. Modabber F. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 1989, 98(Suppl.):S49-S60.
4. Uzonna J.E., Wei G., Yurkowski D., Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 2001, 167(12):6967-6974.
5. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002, 420(6915):502-507.
6. Okwor I., Liu D., Beverley S.M., Uzonna J.E. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci USA 2009.
7. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260(5107):547-549.
8. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263(5144):235-237.
9. Sypek J.P., Chung C.L., Mayor S.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993, 177(6):1797-1802.
10. Yamakami K., Akao S., Sato M., Nitta Y., Miyazaki J., Tadakuma T. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol Int 2001, 50(2):81-91.
11. Park A.Y., Hondowicz B.D., Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000, 165(2):896-902.
12. Park A.Y., Scott P. Il-12: keeping cell-mediated immunity alive. Scand J Immunol 2001, 53(6):529-532.
13. Park A.Y., Hondowicz B., Kopf M., Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 2002, 168(11):5771-5777.
14. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999, 96(12):6970-6975.
15. Constantinescu C.S., Hondowicz B.D., Elloso M.M., Wysocka M., Trinchieri G., Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998, 28(7):2227-2233.
16. Titus R.G., Marchand M., Boon T., Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985, 7(5):545-555.
17. Okwor I., Muleme H., Jia P., Uzonna J.E. Altered proinflammatory cytokine production and enhanced resistance to Trypanosoma congolense infection in lymphotoxin beta-deficient mice. J Infect Dis 2009, 200(3):361-369.
18. Armijos R.X., Weigel M.M., Calvopina M., Hidalgo A., Cevallos W., Correa J. Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004, 22(9-10):1320-1326.
19. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-A meta-analysis. Vaccine 2009, 27(35):4747-4753.
20. Liu D., Kebaier C., Pakpour N., Capul A.A., Beverley S.M., Scott P., et al. Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions. Infect Immun 2009, 77(8):3272-3283.
21. Zaph C., Uzonna J., Beverley S.M., Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 2004, 10(10):1104-1110.
22. Liu D., Uzonna J.E. The p110delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets. J Immunol 2010, 184(6):3098-3105.
23. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002, 168(8):3992-4000.
24. Okwor I., Liu D., Uzonna J. Qualitative differences in the early immune response to live and killed Leishmania major: implications for vaccination strategies against Leishmaniasis. Vaccine 2009, 27(19):2554-2562.
25. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999, 17(5):466-472.
26. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351(9115):1540-1543.
27. Marzochi K.B., Marzochi M.A., Silva A.F., Grativol N., Duarte R., Confort E.M., et al. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 1998, 93(2):205-212.
28. Velez I.D., del Pilar Agudelo S., Arbelaez M.P., Gilchrist K., Robledo S.M., Puerta J.A., et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000, 94(6):698-703.
29. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997, 186(7):1137-1147.
30. Aebischer T., Moody S.F., Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun 1993, 61(1):220-226.
31. Aebischer T. Recurrent cutaneous leishmaniasis: a role for persistent parasites?. Parasitol Today 1994, 10(1):25-28.
32. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43(9):1135-1142.
33. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.